Cite
Antiviral therapy inhibited HBV-reactivation and improved long-term outcomes in patients who underwent radiofrequency ablation for HBV-related hepatocellular carcinoma.
MLA
Liu, Jian, et al. “Antiviral Therapy Inhibited HBV-Reactivation and Improved Long-Term Outcomes in Patients Who Underwent Radiofrequency Ablation for HBV-Related Hepatocellular Carcinoma.” World Journal of Surgical Oncology, vol. 21, no. 1, Feb. 2023, pp. 1–11. EBSCOhost, https://doi.org/10.1186/s12957-023-02921-1.
APA
Liu, J., Shen, H., Huang, S., Lin, J., Yan, Z., Qian, G., Lu, Z., Wan, X., Zhang, F., Wang, K., Zhang, Y., & Li, J. (2023). Antiviral therapy inhibited HBV-reactivation and improved long-term outcomes in patients who underwent radiofrequency ablation for HBV-related hepatocellular carcinoma. World Journal of Surgical Oncology, 21(1), 1–11. https://doi.org/10.1186/s12957-023-02921-1
Chicago
Liu, Jian, Hao Shen, Shengyu Huang, Jianbo Lin, Zhenlin Yan, Guojun Qian, Zhenghua Lu, et al. 2023. “Antiviral Therapy Inhibited HBV-Reactivation and Improved Long-Term Outcomes in Patients Who Underwent Radiofrequency Ablation for HBV-Related Hepatocellular Carcinoma.” World Journal of Surgical Oncology 21 (1): 1–11. doi:10.1186/s12957-023-02921-1.